RxDoctor Payments Data

Sudipta Dey, MD

Internal Medicine · Beacon Falls, CTNPI 1538103833

Payments from drug & device makers

$2,721in general payments, 2019–2025

Across 24 payments — averaging $113.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$838
  • Welch Allyn$838
  • Tosoh Bioscience, Inc.$679
  • GSK$299
  • Merck$35
  • AbbVie$20
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$36613%
  • Gifts$67925%
  • Other$1,67562%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Baxter Healthcare1$838
Welch Allyn1$838
Tosoh Bioscience, Inc.1$679
GSK17$299
Merck2$35
AbbVie1$20
Novo Nordisk1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,721 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$179,451
Medicare patients
218
Services billed
4,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin187$208,151
EliquisApixaban90$92,067
TrulicityDulaglutide75$72,098
OzempicSemaglutide68$64,357
RybelsusSemaglutide14$29,785
MounjaroTirzepatide14$18,856
FarxigaDapagliflozin Propanediol16$13,435
SymbicortBudesonide/Formoterol Fumarate12$5,334
Atorvastatin Calcium565$4,366
Breo ElliptaFluticasone/Vilanterol11$4,363
Levothyroxine Sodium319$3,371
Olmesartan Medoxomil201$2,515
Rosuvastatin Calcium243$2,420
Omeprazole188$2,235
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$12$94,14382 claims
GSKBreo Ellipta$299$4,36311 claims
AbbVieSynthroid$20$1,97834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Beacon Falls

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →